X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Unichem Lab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs UNICHEM LAB - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. UNICHEM LAB FRESENIUS KABI ONCO./
UNICHEM LAB
 
P/E (TTM) x 22.1 22.4 98.9% View Chart
P/BV x 3.1 2.4 132.1% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 FRESENIUS KABI ONCO.   UNICHEM LAB
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
UNICHEM LAB
Mar-16
FRESENIUS KABI ONCO./
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs176334 52.7%   
Low Rs79174 45.1%   
Sales per share (Unadj.) Rs37.7146.9 25.7%  
Earnings per share (Unadj.) Rs5.111.9 42.8%  
Cash flow per share (Unadj.) Rs6.716.2 41.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5105.1 40.5%  
Shares outstanding (eoy) m158.2390.84 174.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.41.7 195.3%   
Avg P/E ratio x25.021.4 117.0%  
P/CF ratio (eoy) x18.915.7 120.6%  
Price / Book Value ratio x3.02.4 123.8%  
Dividend payout %016.8 0.0%   
Avg Mkt Cap Rs m20,13523,073 87.3%   
No. of employees `0001.25.7 20.3%   
Total wages/salary Rs m7032,558 27.5%   
Avg. sales/employee Rs Th5,176.22,352.5 220.0%   
Avg. wages/employee Rs Th610.4450.9 135.4%   
Avg. net profit/employee Rs Th699.6190.4 367.3%   
INCOME DATA
Net Sales Rs m5,96313,346 44.7%  
Other income Rs m18192 9.4%   
Total revenues Rs m5,98113,538 44.2%   
Gross profit Rs m1,4301,639 87.3%  
Depreciation Rs m258390 66.1%   
Interest Rs m-2629 -90.3%   
Profit before tax Rs m1,2161,412 86.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-4 0.0%   
Extraordinary Inc (Exp) Rs m-68-35 192.9%   
Tax Rs m342293 116.9%   
Profit after tax Rs m8061,080 74.6%  
Gross profit margin %24.012.3 195.3%  
Effective tax rate %28.120.7 135.7%   
Net profit margin %13.58.1 166.9%  
BALANCE SHEET DATA
Current assets Rs m5,1025,979 85.3%   
Current liabilities Rs m2,3852,432 98.1%   
Net working cap to sales %45.626.6 171.4%  
Current ratio x2.12.5 87.0%  
Inventory Days Days15063 237.9%  
Debtors Days Days11360 187.6%  
Net fixed assets Rs m5,1486,403 80.4%   
Share capital Rs m158182 87.1%   
"Free" reserves Rs m6,5569,293 70.5%   
Net worth Rs m6,7329,548 70.5%   
Long term debt Rs m952230 413.3%   
Total assets Rs m10,38812,843 80.9%  
Interest coverage x-45.850.0 -91.5%   
Debt to equity ratio x0.10 586.2%  
Sales to assets ratio x0.61.0 55.2%   
Return on assets %7.58.6 86.9%  
Return on equity %12.011.3 105.8%  
Return on capital %14.614.3 101.9%  
Exports to sales %74.529.2 254.9%   
Imports to sales %24.86.3 390.5%   
Exports (fob) Rs m4,4413,900 113.9%   
Imports (cif) Rs m1,477847 174.5%   
Fx inflow Rs m5,2984,356 121.6%   
Fx outflow Rs m1,7721,162 152.5%   
Net fx Rs m3,5253,194 110.4%   
CASH FLOW
From Operations Rs m1,2741,119 113.9%  
From Investments Rs m-1,204-853 141.1%  
From Financial Activity Rs m-196-334 58.7%  
Net Cashflow Rs m-126-68 184.9%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 15.1 2.0%  
FIIs % 9.6 3.0 320.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 31.7 28.7%  
Shareholders   42,599 20,176 211.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  MERCK LTD  NOVARTIS  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - SUN PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS